Formulations for parenteral use of estramustine phosphate and sulfoalkyl ether cyclodextrins
AssigneePharmacia Italia S.p.A.
InventorsLorena Muggetti, Paolo Colombo, Alessandro Martini, Giovanni Buzzi
Life of this patent
Estimating the term…
Abstract
A pharmaceutical formulation which comprises a parenterally acceptable carrier or diluent, estramustine phosphate and a sulfoalkyl ether cyclodextrin. The formulation can be administered according to a combined chemotherapy regimen in association with one or more chemotherapeutic agents. The formulation also enables estramustin phosphate to be administered with no side effects at the site of injection.
Claims22
A pharmaceutical formation which comprises a parenterally acceptable carrier or diluent and estramustine phosphate and a sulfoalkyl ether cyclodextrine.
A product which comprises
- (i) a pharmaceutical formulation which comprises a parenterally acceptable carrier or diluent, estramustine phosphate and a sulfoalkyl ether cyclodextrin, and
- (ii) one or more chemotherapeutic agents;
- as a combined preparation for simultaneous, separate or sequential use in anticancer therapy.
A product which comprises estramustine phosphate in lyophilized form and a physiological solution for parenteral use containing a sulfoalkyl ether cyclodextrin.
Dependencies are inferred from the claim text.